Industry News
Pharmaceutical Industry News
Novo Nordisk turned in sales and…
Novo Nordisk turned in sales and profit growth in 2025 amid an intense obesity market rivalry with Eli Lilly. But investor optimism came to a sudden halt Tuesday as the company warned of significant sales
To stir up support for the fight…
To stir up support for the fight against cancer, Pfizer has turned to one of the most iconic pep talks of all time.
Charles River Laboratories is…
Charles River Laboratories is continuing its run of layoffs by announcing the closure of its cell therapy contract development and manufacturing organization (CDMO) site in Hanover, Maryland that will cost the company 20 jobs.
As top-selling Keytruda inches…
As top-selling Keytruda inches closer to its 2028 patent cliff, Merck's confidence in sustainable growth for the future is "as high as it's ever been," CEO Robert Davis said on the company's full-year 2025 earnings
La ostarina, el fármaco que está en el centro del dopaje deportivo
El fármaco prometía profundos cambios en tratamientos médicos. Algo inesperado ocurrió en el camino hacia la aprobación de la FDA.
AstraZeneca will have to negotiate…
AstraZeneca will have to negotiate what appears to be a minor speed bump in order to gain clearance in the U.S. for its subcutaneous version of lupus treatment Saphnelo. The FDA has rejected AZ's application
Nanologica, a life sciences…
Nanologica, a life sciences company that makes silica-based peptides for the pharmaceutical industry, acquired CDMO Ardena’s Syntagon manufacturing facility in a stock deal valued at 8.6 million Swedish kroner ($961,000).
A U.K. marketing watchdog has…
A U.K. marketing watchdog has sanctioned Sanofi after ruling its CEO Paul Hudson may have undermined the U.K. government’s vaccine program by making “bold claims” about a procurement choice.
The Key to Managing Tariffs: Be Big and Have the President’s Ear
Several large American manufacturers are thriving despite the threat of higher costs. Smaller ones are struggling.
With Valentine’s Day coming up,…
With Valentine’s Day coming up, AbbVie has love on the brain. Ahead of the holiday, the Big Pharma has unveiled a new campaign focusing on how migraines can impact romantic relationships.
The FDA issued complete response…
The FDA issued complete response letters to Aquestive Therapeutics and Pharming in recent days, resulting in vastly different reactions from the market.
Thermo Fisher is continuing its…
Thermo Fisher is continuing its recent layoff spree with a fresh round of cuts tied to a site it’s shuttering in Franklin, Massachusetts, which currently employs about 200 people.
Amid an outpouring of industry…
Amid an outpouring of industry investments in U.S. drug production, the FDA has launched a new program designed to reduce the complexities involved in setting up domestic manufacturing plants.
The Wonder Drug That’s Plaguing Sports
Ostarine held the promise of profound medical treatments. Something unexpected happened on the way to F.D.A. approval.
Sanofi, Novo Nordisk, UCB and…
Sanofi, Novo Nordisk, UCB and others received positive opinions from Europe's Committee for Medicinal Products for Human Use, while Amgen's approved Tavneos is up for a re-review due to data integrity concerns.
For the last several quarters,…
For the last several quarters, declining sales of Regeneron's eye disease treatment Eylea have exceeded increasing sales of the drug's new version, Eylea HD, leading to a steady decline in overall U.S. sales for the
Quince Therapeutics’ novel…
Quince Therapeutics’ novel method of delivering steroids in a patient’s own red blood cells turned out to be a bust in ataxia-telangiectasia, a rare inherited disorder, with the company now planning to “preserve cash and
On Friday, Eli Lilly unveiled…
On Friday, Eli Lilly unveiled designs on a new, $3.5 billion manufacturing facility in Pennsylvania’s Lehigh Valley, rounding out the quartet of plants it promised during its “Lilly in America” investment announcement last year.
Some officials in the Trump…
Some officials in the Trump administration are at odds with others who are helping shape vaccine policy over whether to remove COVID vaccines from the U.S. market, according to a report from Axios.
The German CDMO devoted 480…
The German CDMO devoted 480 million euros ($574.3 million) to the first construction phase for a new plant in Saarlouis, Germany, which is expected to be operational by 2031.